Targeted suppression of β-catenin blocks intestinal adenoma formation in APC min mice

Journal of Gastrointestinal Surgery

Volumn 12, Issue 8, 2008, Pages 1452-1458

  Foley, Paul J ^a   Scheri, Randall P ^b   Smolock, Christopher J ^a   Pippin, James ^a   Green, Douglas W ^a,b   Drebin, Jeffrey A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenoma; Beta catenin; Chemoprevention; Colon cancer

Indexed keywords

BETA CATENIN; CATNB PROTEIN, MOUSE; RNA;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; COLON POLYPOSIS; COLON TUMOR; COMPARATIVE STUDY; DISEASE COURSE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MOUSE; NORTHERN BLOTTING; TREATMENT OUTCOME; WESTERN BLOTTING;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; BETA CATENIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RNA, NEOPLASM; TREATMENT OUTCOME;

EID: 48849104247     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-008-0519-6     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society, 2007.
2. Potter J. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999;91:916-932.
3. Cadigan K, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-3305.
4. Novak A, Dedhar S. Signaling through b-catenin and Lef/Tcf. Cell Mol Life Sci 1999;56:523-537.
5. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis A, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H. The b-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-250.
6. Alexander N, Wong C, Pignatelli M. b-Catenin-A linchpin in colorectal carcinogenesis. Am J Pathol 2002;160:389-401.
7. He T, Sparks A, Rago C, Hermeking H, Zawel L, da Costa L, Morin P, Vogelstein B, Kinzler K. Identification of c-myc as a target of the APC pathway. Science 1998;281:1509-1512.
8. Tetsu O, McCormick F. b-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
9. Mann B, Gelos M, Siedow A, Hanski M, Gratchev A, Ilyas M, Bodmer W, Moyer M, Rieken E, Buhr H, Hanski C. Target genes of b-catenin-T cell-factor/ lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A 1999;96:1603-1608.
10. Lin Y, Ono K, Satoh S, Ishiguro H, Fujita M, Miwa N, Tanaka T, Tsunoda T, Yang K, Nakamura Y, Furukawa Y. Identification of AF17 as a downstream gene of the b-catenin/T-cell factor pathway and its involvement in colorectal carcinogenesis. Cancer Res 2001;61:6345-6349.
11. He T, Chan T, Vogelstein B, Kinzler K. PPARd is an APC-regulated target of nonsteroidal anti-inflammatory drug. Cell 1999;99:335-345.
12. Powell S, Zilz N, Beazer-Barklay T, Bryan T, Hamilton S, Thibodeau S, Vogelstein B, Kinzler K. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-237.
13. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001;1:55-67.
14. Kinzler K, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
15. Sparks A, Morin P, Vogelstein B, Kinzler K. Mutational analysis of the APC/beta-catenin/TCF pathway in colorectal cancer. Cancer Res 1998;58:1130-1134.
16. Kinzler K, Nilbert M, Su L, Vogelstein B, Bryan T, Levy D, Smith K, Preisinger A, Hedge P, McKechnie D, Finniear R, Markham A. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-665.
17. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsonomiya J, Baba S, Hedge P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-669.
18. Lynch H, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-932.
19. Su L, Kinzler K, Vogelstein B, Preisinger A, Moser A, Luongo C, Gould K, Dove W. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1991;256:668-670.
20. Roh H, Green D, Boswell C, Pippin J, Drebin J. Suppression of b-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 2001;61:6563-6568.
21. Green D, Roh H, Pippin J, Drebin J. b-Catenin antisense treatment decreases β-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res 2001;101:16-20.
22. Verma U, Surabhi R, Schmaltieg A, Becerra C, Gaynor R. Small interfering RNAs directed against b-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-1300.
23. Corpet D, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
24. McEntee M, Chiu C-H, Whelan J. Relationship of b-catenin and bcl-2 expression to sulindac-induced regression of intestinal tumors in min mice. Carcinogenesis 1999;20:635-640.
25. Oikannen S, Pajari A, Mutanen M. Chemopreventive activity of hydroksymatairesinol in adenomatous polyposis colimultiple intestinal neoplasia (APC)min mice. Cancer Letters 2000;159:183-187.
26. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, Taketo M, Evans J. Chemoprevention of intestinal polyposis in the APCD716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-1740.
27. Schmelz E, Roberts P, Kustin E, Lemonnier L, Sullards C, Dillehay D, Merrill A. Modulation of intracellular b-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 2001;61:6723-6729.
28. Williams J, Nath N, Chen J, Hundley T, Gao J, Kopelovich L, Kashfi K, Rigas B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and b-catenin/T-cell factor signaling, nuclear factor-κB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 2003;63:7613-7618.
29. Orner G, Dashwood W, Blum C, Diaz D, Li Q, Dashwood R. Suppression of tumorigenesis in the APC min mouse: downregulation of b-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 2003;24:263-267.
30. Boon E, Keller J, Wormhoudt T, Giardiello G, Offerhaus G, van der Neut R, Pals S. Sulindac targets nuclear b-catenin accumulation and Wnt signaling in adenomas of patients with familial adenomatous polyposis in human colorectal cancer cell lines. Br J Cancer 2004;90:224-229.
31. Dihlmann S, von Knebel Doeberitz M. Wnt/b-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005;113:515-524.
32. Kashfi K, Rigas B. Non-cox-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 2005;70:969-986.